Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer
- K. M. Islam(corresponding author),
- T. Anggondowati,
- P. E. Deviany,
- J. E. Ryan,
- A. Fetrick,
- D. Bagenda
- ,
- University of Nebraska Medical Center,
- Nebraska Cancer Coalition,
- Marry Lanning Healthcare System,
- St Luke Hospital Kansas City,
- Avera Health
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Background: In the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. Methods: An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Results: Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Conclusions: Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Article number
835Journal (Volume, Issue Number)
BMC Cancer (Volume 19, Issue 1)Publication milestones
- Published - 08/27/2019
Publication status
Published - 08/27/2019
ISSN
1471-2407Publication IDs
- Scopus: 85071537628
- PubMed: 31455252
Publication metrics
Metrics
SciVal
citations
12
SciVal
FWCI
1.53
SciVal
Author count
14
SciVal
Paper percentile
91
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.07
Fractional count
13
Fractional count
0.93
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
131
Citation count
75
Funding Details
This research project was supported by the Patient-Centered Outcomes Research Institute (PCORI) Contract # CE-12-11-4351. The contents are solely the responsibility of the authors and do not necessarily represent the official views of PCORI.
The study was funded by the PCORI (Contract# CE-12-11-4351. The funding agency has no role in the study development, implementation, and publication of study findings.
FundersFunding numbers
PCORI
CE-12-11-4351
PCORI
CE-12-11-4351
